2.125
price down icon5.13%   -0.115
 
loading
전일 마감가:
$2.24
열려 있는:
$2.3
하루 거래량:
131.58K
Relative Volume:
0.69
시가총액:
$67.18M
수익:
-
순이익/손실:
$-14.14M
주가수익비율:
-2.3098
EPS:
-0.92
순현금흐름:
$-12.64M
1주 성능:
-5.13%
1개월 성능:
+7.87%
6개월 성능:
-5.13%
1년 성능:
-0.23%
1일 변동 폭
Value
$2.05
$2.31
1주일 범위
Value
$2.05
$2.4289
52주 변동 폭
Value
$1.26
$3.00

Immix Biopharma Inc Stock (IMMX) Company Profile

Name
명칭
Immix Biopharma Inc
Name
전화
(888) 958-1084
Name
주소
11400 WEST OLYMPIC BLVD., LOS ANGELES
Name
직원
21
Name
트위터
Name
다음 수익 날짜
2024-12-09
Name
최신 SEC 제출 서류
Name
IMMX's Discussions on Twitter

IMMX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
IMMX
Immix Biopharma Inc
2.125 67.18M 0 -14.14M -12.64M -0.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.12 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
519.20 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
318.71 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
558.90 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.45 28.51B 3.81B -644.79M -669.77M -6.24

Immix Biopharma Inc 주식(IMMX)의 최신 뉴스

pulisher
Jun 10, 2025

Jane Street Group LLC Invests $39,000 in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial - MSN

Jun 10, 2025
pulisher
Jun 07, 2025

Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock? - MSN

Jun 07, 2025
pulisher
Jun 07, 2025

Q3 EPS Estimates for Immix Biopharma Raised by HC Wainwright - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Immix Biopharma Attends FDA CEO Forum in Washington DC - GlobeNewswire

Jun 06, 2025
pulisher
Jun 06, 2025

ImmixBio Joins Elite Pharma Leaders at FDA Commissioner's Strategic Forum on Drug Development - Stock Titan

Jun 06, 2025
pulisher
Jun 06, 2025

Immix Biopharma — ASCO/KOL event reaffirms NXC-201’s potential - Smartkarma

Jun 06, 2025
pulisher
Jun 06, 2025

HC Wainwright Comments on Immix Biopharma Q1 Earnings - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Immix Biopharma (NASDAQ:IMMX) Receives Buy Rating from HC Wainwright - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Immix Biopharma (IMMX) Achieves Significant Clinical Milestone w - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

immix biopharma enters at-the-market offering agreement - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

H.C. Wainwright reaffirms Immix Biopharma stock Buy rating after trial By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

H.C. Wainwright reaffirms Immix Biopharma stock Buy rating after trial - Investing.com

Jun 04, 2025
pulisher
Jun 04, 2025

Immix Biopharma’s NXC-201 Achieves 70% Complete Response Rate in AL Amyloidosis Trial - Insider Monkey

Jun 04, 2025
pulisher
Jun 04, 2025

Immix Biopharma (IMMX) Receives Reiterated 'Buy' Rating from HC - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Immix Biopharma (IMMX) Receives Reiterated 'Buy' Rating from HC Wainwright & Co. | IMMX Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Immix Biopharma Announces Primary Endpoint Met in positive - GlobeNewswire

Jun 04, 2025
pulisher
Jun 04, 2025

Immix Biopharma stock soars to 52-week high of $2.99 By Investing.com - Investing.com India

Jun 04, 2025
pulisher
Jun 04, 2025

Immix Biopharma reports high response rate in AL Amyloidosis trial By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 03, 2025

immix biopharma enters at-the-market offering agreement By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

Immix Biopharma's NXC-201 Trial Meets Primary Endpoint in AL Amyloidosis - MarketScreener

Jun 03, 2025
pulisher
Jun 03, 2025

Immix Biopharma stock soars to 52-week high of $2.99 - Investing.com Australia

Jun 03, 2025
pulisher
Jun 03, 2025

Immix Biopharma Enters At The Market Offering Agreement - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

Immix Biopharma reports high response rate in AL Amyloidosis trial - Investing.com

Jun 03, 2025
pulisher
Jun 03, 2025

Immix Biopharma Reports 70% Complete Response Rate for NXC-201 in Phase 1/2 AL Amyloidosis Trial at ASCO 2025 - Nasdaq

Jun 03, 2025
pulisher
Jun 03, 2025

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ... - Eagle-Tribune

Jun 03, 2025
pulisher
May 29, 2025

Immix Biopharma — Positive newsflow continues for NEXICART-2 - Smartkarma

May 29, 2025
pulisher
May 23, 2025

Immix Biopharma accelerates NEXICART-2 trial enrollment By Investing.com - Investing.com South Africa

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma Further Expands U.S. Clinical Sites for Relapsed/Refractory AL Amyloidosis Trial Nexicart-2 - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma (IMMX) Expands NEXICART-2 Trial Sites | IMMX Sto - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma (IMMX) Expands NEXICART-2 Trial Sites | IMMX Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma accelerates NEXICART-2 trial enrollment - Investing.com

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Immix Amyloidosis Trial Surges: 10 New Sites Added, ASCO Data Presentation Coming - Stock Titan

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma (NASDAQ:IMMX) Trading Up 15.3% – Should You Buy? - Defense World

May 23, 2025
pulisher
May 22, 2025

Immix Biopharma reports promising trial results for NXC-201 - Investing.com Australia

May 22, 2025
pulisher
May 22, 2025

Immix Biopharma reports promising trial results for NXC-201 By Investing.com - Investing.com Nigeria

May 22, 2025
pulisher
May 22, 2025

Immix Biopharma Reports Positive ASCO Abstract Results for NXC-201 from NEXICART-2 Trial in Relapsed/Refractory AL Amyloidosis - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Immix Biopharma Announces Positive Results for NXC-201 at - GlobeNewswire

May 22, 2025
pulisher
May 22, 2025

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - Yahoo Finance

May 22, 2025
pulisher
May 22, 2025

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling ... - Eagle-Tribune

May 22, 2025
pulisher
May 21, 2025

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis - The Manila Times

May 21, 2025
pulisher
May 21, 2025

Immix Biopharma to Host KOL Event to Discuss NXC-201 - GlobeNewswire

May 21, 2025
pulisher
May 19, 2025

We're Keeping An Eye On Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate - Yahoo Finance

May 19, 2025
pulisher
May 19, 2025

Immix Biopharma — Steady progress in Q125 - Smartkarma

May 19, 2025

Immix Biopharma Inc (IMMX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Immix Biopharma Inc 주식 (IMMX) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Morris Gabriel S
CFO
Jun 18 '25
Buy
2.28
2,225
5,071
288,059
Hsu Jason
Director
Dec 23 '24
Buy
2.19
40,000
87,680
893,000
Hsu Jason
Director
Dec 20 '24
Buy
2.17
7,700
16,678
853,000
Hsu Jason
Director
Aug 21 '24
Buy
2.23
15,000
33,390
837,200
Hsu Jason
Director
Aug 22 '24
Buy
2.25
8,100
18,233
845,300
Ng Carey
Director
Aug 16 '24
Buy
1.86
10,000
18,600
20,000
Hsu Jason
Director
Jul 24 '24
Buy
2.15
6,000
12,877
822,200
Hsu Jason
Director
Jul 18 '24
Buy
2.07
3,200
6,639
816,200
$20.42
price down icon 1.37%
$35.45
price up icon 0.65%
$21.06
price down icon 1.92%
$101.83
price down icon 0.41%
$105.86
price down icon 0.39%
biotechnology ONC
$244.00
price down icon 3.69%
자본화:     |  볼륨(24시간):